The Prospectus Supplement has been prepared due to the fact that ChromoGenics board of directors may settle the guarantee compensation to the guarantors by means of a directed issue of maximum 500,000 shares and, in accordance with the provisions of the Offer, by allotment of one warrant for each share without consideration (together one “Unit”). In total, a maximum of 500,000 Units can be allotted to the guarantors as guarantee compensation. The Prospectus Supplement has today been approved by the Swedish Financial Supervisory Authority and is available at www.chromogenics.com
Investors who, prior to the publication of the Prospectus Supplement, have notified or otherwise agreed to subscribe for Units in the Offer are, in accordance with Chapter 2, Section 34, of the Swedish Financial Instruments Trading Act (1991:980), entitled to withdraw their notification or consent within two working days from the publication of the Prospectus Supplement, i.e. on 24 February 2017 at the latest. The withdrawal must be made in writing and submitted to Aktieinvest FK AB, Emittentservice, 113 89 Stockholm, Sweden. Investors who have subscribed through a nominee should contact their nominee regarding withdrawal. Subscriptions that are not withdrawn will remain in force. Should subscribers wish to remain as subscribers no action is required.
G&W Fondkommission is the financial advisor in connection with the Offer and will be the company’s Certified Advisor on Nasdaq First North. Hannes Snellman Attorneys Ltd is the legal advisor in relation to Swedish law in connection with the offer.
This information is such that ChromoGenics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 12:00 CET on February 22, 2017.
Thomas Almesjö, CEO
Susanne Andersson, CFO & Head of Communications
Tel: +46 18 430 0430
This document has not been approved by any regulatory authority. The document is a press release and not a prospectus and investors should not subscribe for or purchase any securities referred to in this document except on the basis of the information contained in the prospectus which has been approved by the FSA and will be available on the company website. The distribution of this announcement in certain jurisdictions may be restricted by law, and persons who access it or any part of it, should inform themselves and observe such restrictions. This press release shall not constitute an offer to sell or a solicitation to buy shares, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of additional prospectuses or other documentation, or be unlawful prior to registration or applicable exemption from registration under the securities laws of such jurisdiction.
This press release does not constitute or form part of, an offer or the solicitation of an offer to buy or subscribe for securities in the United States. The securities mentioned herein have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the United States absent registration under the Securities Act, or an exemption therefrom. The securities mentioned herein are not offered to the public in the United States. Copies of this announcement are not being, and must not be distributed or sent, in whole or in part, directly or indirectly, in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States or any other jurisdiction where such distribution and the mailing of this press release would be unlawful.
ChromoGenics is a leader in dynamic glass with controllable heat- and light transmission. The company’s unique electrochromic technology ConverLight™, provides sustainable solar control with increased indoor comfort and energy efficiency. In 2016 the company started sales and deliveries to real estate projects in Scandinavia.
ChromoGenics is located in Uppsala and the technology is derived from the world leading research center at Ångström Laboratory at Uppsala University. The company has about 20 employees and the main owners are K-Svets Venture AB and New Energy Solutions II K/S. The plant has been partly financed by a conditional loan from the Swedish Energy Agency. www.chromogenics.com